Drug Type Antibody fusion proteins |
Synonyms |
Target |
Mechanism IL-21R agonists(Interleukin 21 Receptor agonists), IL-2Rβγ agonists(Interleukin-2 Rβγ agonists), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | CN | 12 Apr 2022 |